AnaBios News

SAN DIEGO, CA – September 17, 2019 – The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes).  Funds from the grant will be used to develop a preclinical biomarker to identify the pro-arrhythmia risk of potential drugs based on contractility measurements in human adult primary cardiomyocytes. AnaBios’ cardiomyocyte research has yielded highly translational information about cellular properties and drug-induced variations in cardiac function. “AnaBios is honored to receive this grant from the FDA for this critical project [...]

SAN DIEGO, CA – August 13, 2019 – AnaBios Corp. today announced it is providing validated human dorsal root ganglion (hDRG) to the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), for research collaborations to develop human cell-based screening platforms and novel drugs to treat pain and opioid use disorder. The collaborations are part of the NIH HEAL (Helping End Addiction Long-term) Initiative. Dorsal root ganglion neurons are surgically recovered by AnaBios from ethically consented organ donors. These tissue samples from the peripheral nervous system comprise the human sensory neurons that [...]

SAN DIEGO, CA – October 5, 2018 – A San Diego based bio tech company is developing a non opioid procedure to treat chronic pain. Dr. Andrew Ghetti is the CEO at AnaBios Corporation , which is the first in the world to use human neurons for advancing pain drugs. He tells KOGO news models with rats and mice don't usually work. He says drugs that seem to do wonders in animals are completely ineffective or outright toxic in humans AnaBios' approach is to treat the nerve paths with a series of drugs targeting molecules in the body called [...]

SAN DIEGO, CA – August 28, 2018 – AnaBios, the leader in translational pain research, will present its clinical candidates for the treatment of chronic pain at the 17th IASP World Congress on Pain on September 12 in Boston, Mass. The molecules—part of AnaBios’ advanced internal drug discovery program—have a novel selectivity profile and properties, targeting ion channels highly expressed in pathological states associated with pain. “We are very encouraged by the results obtained thus far from these novel compounds and believe they present a significant opportunity for developing non-opioid therapeutics to treat chronic pain,” said Dr. Andre Ghetti, [...]

SAN DIEGO, CA – May 22, 2018 – AnaBios is pleased to announce the recent hire of Chris Mathes, Ph.D., MBA, as Chief Commercial Officer. Within this new role, Mathes will guide the company’s business development endeavors and contribute to AnaBios’ overall strategic direction as it leverages its proven drug de-risking technology based on ex vivo human pharmacological responses. Mathes joins AnaBios from early drug discovery company Icagen, where he was Chief Commercial Officer. Prior to that, he served as Chief Commercial Officer at ChanTest, now part of Charles River, and headed up North American business development activities for [...]

SAN DIEGO, CA – February 8, 2018 – AnaBios announced today a partnership with Sanofi to develop a new treatment for atrial fibrillation. The program will focus on compounds designed to modulate a novel cardiac ion channel target. Through this agreement, AnaBios will acquire development and commercialization rights to an entire family of promising compounds addressing the global atrial fibrillation market, which is estimated to reach $16.17 billion by 2020 according to a recent report by Grand View Research. “Our new partnership with Sanofi, a global healthcare leader, validates the tremendous accomplishments of AnaBios in developing a human tissue- [...]

SAN DIEGO, CA – January 22, 2018 – First-of-its-kind preclinical ex-vivo human cardiac research conducted by AnaBios and Amgen, published today in the journal Frontiers in Physiology, demonstrates that isolated human heart-based model, combined with the integrated analysis using newly-developed pro-arrhythmic score, can differentiate between pro-arrhythmic and non-pro-arrhythmic compounds and has a greater predictivity when compared to models derived from human stem cells. “Our innovative translational approaches enable human-focused drug discovery and help ensure the safety and efficacy of new treatments,” said Dr. Andre Ghetti, Chief Executive Officer of AnaBios. “Data from this research demonstrates that isolated adult human [...]

"Frontiers in Physiology," one of the world's leading physiology research journals, published research regarding AnaBios' adult human primary cardiomyocyte-based model that has the potential to predict drug-induced inotropic and pro-arrhythmia risks at the preclinical phase. To view the article, visit the "Frontiers in Physiology" website.

The Pain Research Forum highlighted AnaBios CEO Dr. Andre Ghetti's recent presentation at the 11th Annual Pain and Migraine Therapeutics Summit in San Diego, California. Dr. Ghetti discussed the importance of utilizing human DRG neurons early in the drug discovery process to accurately predict human responses to molecular compounds.From the article:The human DRG neurons, Ghetti said, have great predictive value for development of pharmaceutical agents. For example, one compound—an unnamed sodium channel blocker—showed promise in rodents, halting firing of action potentials in DRG neurons and reversing hypersensitivity in vivo. But the compound had no effect on human DRG neurons, even [...]

AnaBios Scientific Director Najah Abi-Gerges, PhD, will present "Adult Human Primary Cardiomyocyotes: An Integrative Translational Model for Cardiotoxicity Assessment" on Thursday, November 2, from 11am-12pm EDT. Drug-induced irregular heart beat (pro arrhythmia) and/or changes in contractility (inotropic liability) can limit the utility of potential novel therapeutics. Since abnormal ventricular repolarization can cause not only electrical disorders, but also affect the heart’s contractile function, the main motivation of this study was to develop a new model based on adult human primary cardiomyocytes to provide a preclinical tool for the simultaneous prediction of drug-induced inotropic and pro-arrhythmia risks. To facilitate the scalability [...]

Thursday, March 16th from 8:30 am to 11:45 am: "A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk." Hall A of the Exhibit Hall (Dr. Najah Abi-Gerges). If you will be at the meeting in March, please contact Alisen James: ajames@anabios.com, to let us know. We forward to connecting with both colleagues and clients.  

Tuesday, March 14th - 9:30 am to 12:45 pm: "Adult Human Primary Cardiomyocytes: An Integrative Translational Model for Cardiotoxicity Assessment." Hall A of the Exhibit Hall area (Dr. Najah Abi-Gerges)